Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trial
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-07-01
|
| Series: | Cell Discovery |
| Online Access: | https://doi.org/10.1038/s41421-025-00813-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849345332304936960 |
|---|---|
| author | Yanling Wu Yuan Li Ping Zhang Siwei Guo Fang Yuan Vivian Liu Ting Yu Feng Lin Nan Yang Chao Tu Hongzhou Lu Tianlei Ying Xin Li |
| author_facet | Yanling Wu Yuan Li Ping Zhang Siwei Guo Fang Yuan Vivian Liu Ting Yu Feng Lin Nan Yang Chao Tu Hongzhou Lu Tianlei Ying Xin Li |
| author_sort | Yanling Wu |
| collection | DOAJ |
| format | Article |
| id | doaj-art-8d3eb168e3d149e5ae6a4a8ba3400abb |
| institution | Kabale University |
| issn | 2056-5968 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Cell Discovery |
| spelling | doaj-art-8d3eb168e3d149e5ae6a4a8ba3400abb2025-08-20T03:42:30ZengNature Publishing GroupCell Discovery2056-59682025-07-011111410.1038/s41421-025-00813-0Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trialYanling Wu0Yuan Li1Ping Zhang2Siwei Guo3Fang Yuan4Vivian Liu5Ting Yu6Feng Lin7Nan Yang8Chao Tu9Hongzhou Lu10Tianlei Ying11Xin Li12Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Department of Pulmonary and Critical Care Medicine, Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan UniversityDepartment of Pharmacy, The Third Hospital of ChangshaDepartment of Pharmacy, The Third Hospital of ChangshaDepartment of Pharmacy, The Third Hospital of ChangshaDepartment of Pharmacy, The Third Hospital of ChangshaBiomissile (Anji) Pharmaceuticals Co., LtdBiomissile (Anji) Pharmaceuticals Co., LtdDepartment of Infectious Diseases, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical UniversityThe Third Hospital of Hebei Medical UniversityBiomissile (Anji) Pharmaceuticals Co., LtdNational Clinical Research Center for Infectious Diseases, The Third People’s Hospital of Shenzhen and The Second Affiliated Hospital of Southern University of Science and TechnologyKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Department of Pulmonary and Critical Care Medicine, Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan UniversityDepartment of Pharmacy, The Third Hospital of Changshahttps://doi.org/10.1038/s41421-025-00813-0 |
| spellingShingle | Yanling Wu Yuan Li Ping Zhang Siwei Guo Fang Yuan Vivian Liu Ting Yu Feng Lin Nan Yang Chao Tu Hongzhou Lu Tianlei Ying Xin Li Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trial Cell Discovery |
| title | Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trial |
| title_full | Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trial |
| title_fullStr | Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trial |
| title_full_unstemmed | Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trial |
| title_short | Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trial |
| title_sort | inhaled bispecific single domain antibody bm219 for mild to moderate covid 19 a double blind randomized placebo controlled phase 2 trial |
| url | https://doi.org/10.1038/s41421-025-00813-0 |
| work_keys_str_mv | AT yanlingwu inhaledbispecificsingledomainantibodybm219formildtomoderatecovid19adoubleblindrandomizedplacebocontrolledphase2trial AT yuanli inhaledbispecificsingledomainantibodybm219formildtomoderatecovid19adoubleblindrandomizedplacebocontrolledphase2trial AT pingzhang inhaledbispecificsingledomainantibodybm219formildtomoderatecovid19adoubleblindrandomizedplacebocontrolledphase2trial AT siweiguo inhaledbispecificsingledomainantibodybm219formildtomoderatecovid19adoubleblindrandomizedplacebocontrolledphase2trial AT fangyuan inhaledbispecificsingledomainantibodybm219formildtomoderatecovid19adoubleblindrandomizedplacebocontrolledphase2trial AT vivianliu inhaledbispecificsingledomainantibodybm219formildtomoderatecovid19adoubleblindrandomizedplacebocontrolledphase2trial AT tingyu inhaledbispecificsingledomainantibodybm219formildtomoderatecovid19adoubleblindrandomizedplacebocontrolledphase2trial AT fenglin inhaledbispecificsingledomainantibodybm219formildtomoderatecovid19adoubleblindrandomizedplacebocontrolledphase2trial AT nanyang inhaledbispecificsingledomainantibodybm219formildtomoderatecovid19adoubleblindrandomizedplacebocontrolledphase2trial AT chaotu inhaledbispecificsingledomainantibodybm219formildtomoderatecovid19adoubleblindrandomizedplacebocontrolledphase2trial AT hongzhoulu inhaledbispecificsingledomainantibodybm219formildtomoderatecovid19adoubleblindrandomizedplacebocontrolledphase2trial AT tianleiying inhaledbispecificsingledomainantibodybm219formildtomoderatecovid19adoubleblindrandomizedplacebocontrolledphase2trial AT xinli inhaledbispecificsingledomainantibodybm219formildtomoderatecovid19adoubleblindrandomizedplacebocontrolledphase2trial |